Skip to main content

Advertisement

Correction to: Bazedoxifene as a novel GP130 inhibitor for Colon Cancer therapy

Article metrics

  • 85 Accesses

The original article was published in Journal of Experimental & Clinical Cancer Research 2019 38:63

Correction to: J Exp Clin Cancer Res

https://doi.org/10.1186/s13046-019-1072-8

In the original publication of this article [1], there is an error in Fig. 4A.

The corrected Fig. 4A should be:

Fig. 4
figure1

Bazedoxifene inhibits induction of STAT3 phosphorylation and cell proliferation by IL-11. a: DLD-1, HCT-116, and HCT-15 cells were starved in serum-free medium for 24 h and pre-treated with bazedoxifene (5~20 μM) for 2 h. Then, 50 ng/ml (DLD-1 cells) or 25 ng/ml IL-11 (HCT-116 and HCT-15 cells), 50 ng/ml OSM (DLD-1 cells) and 50 ng/ml IFN-γ (DLD-1 cells) were added for stimulation. The p-STAT3Y705, p-STAT1Y701, STAT3, STAT1 and GAPDH were assessed by western blot analysis.

Reference

  1. 1.

    Wei, et al. Bazedoxifene as a novel GP130 inhibitor for Colon Cancer therapy. J Exp Clin Cancer Res. 2019;38:63. https://doi.org/10.1186/s13046-019-1072-8.

Download references

Author information

Correspondence to Jiayuh Lin.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article